FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128642677> ?p ?o ?g. }

• W3128642677 endingPage "e045162" @default.
• W3128642677 startingPage "e045162" @default.
• W3128642677 abstract "Introduction Human amniotic fluid (hAF) has been shown to reduce inflammation in multiple experimental models. hAF has previously been approved by the US Food and Drug Administration (FDA) as a human cellular and tissue product for tissue injury for human administration, and used safely in thousands of patients as a therapeutic treatment for diverse conditions. Given the profound inflammatory response observed in patients with COVID-19, and the successful completion of 10-patient pilot study of intravenous hAF, we present a trial design for a larger clinical trial of intravenous hAF for the treatment of COVID-19. Methods and analysis This paper describes the methodology of a phase I/II randomised, double-blinded, placebo-controlled clinical trial to determine the safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19. Primary outcome will be the change in C-reactive protein. Secondary outcomes include safety, biomarker inflammatory levels and clinically relevant outcomes at 30 days, including mortality, ventilator-free days and hospital and intensive care unit length of stay. Exploratory outcomes of health-related quality-of-life patient-reported outcomes will be collected. Hospitalised patients with laboratory-confirmed COVID-19 will be recruited. Ethics and dissemination This study was approved by the University of Utah Institutional Review Board (IRB_0013292), approved by the US FDA under Investigational New Drug (No 23369) and is registered on ClinicalTrials.gov. Results will be disseminated via peer-reviewed publications and conference presentations. Trial registration number NCT04497389 ; Pre-results." @default.
• W3128642677 created "2021-02-15" @default.
• W3128642677 creator A5002846794 @default.
• W3128642677 creator A5006066023 @default.
• W3128642677 creator A5015367254 @default.
• W3128642677 creator A5031493840 @default.
• W3128642677 creator A5034447236 @default.
• W3128642677 creator A5045359084 @default.
• W3128642677 creator A5047956491 @default.
• W3128642677 creator A5051380674 @default.
• W3128642677 creator A5083848579 @default.
• W3128642677 date "2021-02-01" @default.
• W3128642677 modified "2023-09-27" @default.
• W3128642677 title "Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial" @default.
• W3128642677 cites W1761020218 @default.
• W3128642677 cites W2017604106 @default.
• W3128642677 cites W2031789381 @default.
• W3128642677 cites W2080407630 @default.
• W3128642677 cites W2082490993 @default.
• W3128642677 cites W2093274439 @default.
• W3128642677 cites W2116484695 @default.
• W3128642677 cites W2150854138 @default.
• W3128642677 cites W2166023752 @default.
• W3128642677 cites W2317177334 @default.
• W3128642677 cites W2489169965 @default.
• W3128642677 cites W2579980522 @default.
• W3128642677 cites W2604448873 @default.
• W3128642677 cites W2936263379 @default.
• W3128642677 cites W3009155534 @default.
• W3128642677 cites W3010123202 @default.
• W3128642677 cites W3011996301 @default.
• W3128642677 cites W3012690896 @default.
• W3128642677 cites W3016263512 @default.
• W3128642677 doi "https://doi.org/10.1136/bmjopen-2020-045162" @default.
• W3128642677 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7880092" @default.
• W3128642677 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33574155" @default.
• W3128642677 hasPublicationYear "2021" @default.
• W3128642677 type Work @default.
• W3128642677 sameAs 3128642677 @default.
• W3128642677 citedByCount "3" @default.
• W3128642677 countsByYear W31286426772022 @default.
• W3128642677 crossrefType "journal-article" @default.
• W3128642677 hasAuthorship W3128642677A5002846794 @default.
• W3128642677 hasAuthorship W3128642677A5006066023 @default.
• W3128642677 hasAuthorship W3128642677A5015367254 @default.
• W3128642677 hasAuthorship W3128642677A5031493840 @default.
• W3128642677 hasAuthorship W3128642677A5034447236 @default.
• W3128642677 hasAuthorship W3128642677A5045359084 @default.
• W3128642677 hasAuthorship W3128642677A5047956491 @default.
• W3128642677 hasAuthorship W3128642677A5051380674 @default.
• W3128642677 hasAuthorship W3128642677A5083848579 @default.
• W3128642677 hasBestOaLocation W31286426771 @default.
• W3128642677 hasConcept C126322002 @default.
• W3128642677 hasConcept C141071460 @default.
• W3128642677 hasConcept C142724271 @default.
• W3128642677 hasConcept C168563851 @default.
• W3128642677 hasConcept C177713679 @default.
• W3128642677 hasConcept C194828623 @default.
• W3128642677 hasConcept C197934379 @default.
• W3128642677 hasConcept C203092338 @default.
• W3128642677 hasConcept C204787440 @default.
• W3128642677 hasConcept C27081682 @default.
• W3128642677 hasConcept C2777106319 @default.
• W3128642677 hasConcept C2780385302 @default.
• W3128642677 hasConcept C502991105 @default.
• W3128642677 hasConcept C535046627 @default.
• W3128642677 hasConcept C71924100 @default.
• W3128642677 hasConceptScore W3128642677C126322002 @default.
• W3128642677 hasConceptScore W3128642677C141071460 @default.
• W3128642677 hasConceptScore W3128642677C142724271 @default.
• W3128642677 hasConceptScore W3128642677C168563851 @default.
• W3128642677 hasConceptScore W3128642677C177713679 @default.
• W3128642677 hasConceptScore W3128642677C194828623 @default.
• W3128642677 hasConceptScore W3128642677C197934379 @default.
• W3128642677 hasConceptScore W3128642677C203092338 @default.
• W3128642677 hasConceptScore W3128642677C204787440 @default.
• W3128642677 hasConceptScore W3128642677C27081682 @default.
• W3128642677 hasConceptScore W3128642677C2777106319 @default.
• W3128642677 hasConceptScore W3128642677C2780385302 @default.
• W3128642677 hasConceptScore W3128642677C502991105 @default.
• W3128642677 hasConceptScore W3128642677C535046627 @default.
• W3128642677 hasConceptScore W3128642677C71924100 @default.
• W3128642677 hasFunder F4320337338 @default.
• W3128642677 hasFunder F4320337472 @default.
• W3128642677 hasIssue "2" @default.
• W3128642677 hasLocation W31286426771 @default.
• W3128642677 hasLocation W31286426772 @default.
• W3128642677 hasLocation W31286426773 @default.
• W3128642677 hasOpenAccess W3128642677 @default.
• W3128642677 hasPrimaryLocation W31286426771 @default.
• W3128642677 hasRelatedWork W1483408614 @default.
• W3128642677 hasRelatedWork W2064879719 @default.
• W3128642677 hasRelatedWork W2085830368 @default.
• W3128642677 hasRelatedWork W2117916573 @default.
• W3128642677 hasRelatedWork W2766008196 @default.
• W3128642677 hasRelatedWork W3155195005 @default.
• W3128642677 hasRelatedWork W3172359983 @default.
• W3128642677 hasRelatedWork W3197690460 @default.

• next